Norbert Bischofberger ices a PhIII AML drug — for the second time in his career

Norbert Bischofberger went back to his old colleagues at Gilead to pluck an AML drug off its back shelves and put it into the late-stage pipeline at Kronos. And last spring he even worked out a shorter Phase III path at the FDA for the SYK inhibitor using a unique…

...

Click to view original post